Results 171 to 180 of about 7,782 (210)
Some of the next articles are maybe not open access.
Nifurtimox (Lampit) for Chagas Disease
The Medical Letter on Drugs and TherapeuticsThe FDA has approved the nitrofuran antiprotozoal drug nifurtimox (Lampit – Bayer) for treatment of Chagas disease (American trypanosomiasis) in children who weigh ≥2.5 kg. Nifurtimox was previously available in the US only through a CDC-sponsored Investigational New Drug (IND) program.
openaire +2 more sources
Conformational analysis and spectroscopic properties of antichagasic nifurtimox
Spectrochimica Acta Part A: Molecular and Biomolecular SpectroscopyConsidering the health relevance of Chagas' disease, recent research efforts have focused on developing more efficient drug delivery systems containing nifurtimox (NFX). This paper comprehensively investigates NFX through conformational analysis and spectroscopic characterization.
Idejan P. Gross +7 more
openaire +2 more sources
Rat liver nuclear nifurtimox nitroreductase activity.
Research communications in molecular pathology and pharmacology, 1998Nifurtimox (Nfx) 4-[(5-nitrofurfurylidine)amino-3-methylthiomorpholine-1-1-di oxide] is a drug that is being used to treat American Trypanosomiasis (Chagas' disease). Nfx has serious toxic effects including mutagenic, reproductive and carcinogenic actions.
E G, de Toranzo +2 more
openaire +1 more source
Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas’ disease
Journal of Antimicrobial Chemotherapy, 2020Yves Jackson, François Chappuis
exaly
Selected Aspects of the Analytical and Pharmaceutical Profiles of Nifurtimox
Journal of Pharmaceutical Sciences, 2023Aldana Moroni +2 more
exaly